<DOC>
	<DOCNO>NCT00052481</DOCNO>
	<brief_summary>RATIONALE : Quality life assessment patient undergoing prostate cancer treatment may help determine intermediate-term long-term effect surgery brachytherapy . PURPOSE : Randomized clinical trial study quality life patient undergoing radical prostatectomy brachytherapy stage II prostate cancer .</brief_summary>
	<brief_title>Quality Life Patients Undergoing Surgery Brachytherapy Stage II Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare change health-related quality life ( HRQOL ) patient stage II prostate cancer 2 year treatment radical prostatectomy brachytherapy . - Compare effect baseline HRQOL , age , covariates HRQOL improvement deterioration patient 10 year treatment . - Compare effect treatment modality HRQOL improvement deterioration patient 10 year treatment . - Compare effect treatment failure HRQOL , term disease progression , patient . OUTLINE : Patients randomize 1 2 arm ACOSOG-Z0070 ( radical prostatectomy v brachytherapy ) . Patients arm complete quality life questionnaire baseline , 2 6 month treatment , 1 , 2 , 4 , 7 , 10 year treatment . PROJECTED ACCRUAL : A total 500 patient ( 250 per group ) accrue study within 2 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate within past 120 day Stage II disease ( T1cT2a , N0 , M0 ) Concurrent enrollment ACOSOGZ0070 Not yet randomize intervention arm ( radical prostatectomy brachytherapy ) Willing able complete heathrelated quality life questionnaires PATIENT CHARACTERISTICS : Age 75 PRIOR CONCURRENT THERAPY : Endocrine therapy More 6 month since prior hormonal therapy prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>adenocarcinoma prostate</keyword>
</DOC>